1. Home
  2. AMAT vs GILD Comparison

AMAT vs GILD Comparison

Compare AMAT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Applied Materials Inc.

AMAT

Applied Materials Inc.

N/A

Current Price

$370.42

Market Cap

264.0B

Sector

Technology

ML Signal

N/A

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

N/A

Current Price

$169.48

Market Cap

211.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMAT
GILD
Founded
1967
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.0B
211.7B
IPO Year
1994
2003

Fundamental Metrics

Financial Performance
Metric
AMAT
GILD
Price
$370.42
$169.48
Analyst Decision
Strong Buy
Buy
Analyst Count
41
28
Target Price
★ $626.86
$174.77
AVG Volume (30 Days)
6.4M
★ 6.6M
Earning Date
11-12-2026
10-29-2026
Dividend Yield
0.64%
★ 1.97%
EPS Growth
0.58
★ 1684.21
EPS
★ 9.22
N/A
Revenue
$14,608,000,000.00
★ $24,689,000,000.00
Revenue This Year
$20.73
$6.53
Revenue Next Year
$35.41
$6.98
P/E Ratio
$36.09
★ N/A
Revenue Growth
N/A
★ 9.98
52 Week Low
$203.40
$116.88
52 Week High
$739.67
$176.58

Technical Indicators

Market Signals
Indicator
AMAT
GILD
Relative Strength Index (RSI) 40.78 63.03
Support Level $321.22 $142.91
Resistance Level $394.41 N/A
Average True Range (ATR) 18.24 4.83
MACD -3.51 0.61
Stochastic Oscillator 45.93 71.17

Price Performance

Historical Comparison
AMAT
GILD

About AMAT Applied Materials Inc.

Applied Materials is the largest semiconductor wafer fabrication equipment manufacturer in the world. It has a broad portfolio spanning nearly every corner of the WFE ecosystem. Applied Materials holds leading market share in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: